| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
6-Hydroxyluteolin 7-glucoside acts primarily as a 15-lipoxygenase (15-LOX) inhibitor with an IC50 of 2.35 μM, demonstrating selective anti-inflammatory activity with minimal off-target toxicity. It inhibits the major pathways of arachidonic acid metabolism in leukocytes, thereby reducing the production of inflammatory mediators. The compound also modulates key signaling pathways involved in oxidative stress response and immune regulation. The 7-O-glucoside moiety significantly alters its pharmacokinetic behavior and in vitro potency compared to the aglycone form, with a 17-fold difference observed in xanthine oxidase assays.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that 6-hydroxyluteolin 7-glucoside exhibits potent 15-LOX inhibition with an IC50 of 2.35 μM. The compound upregulates collagen type I expression in human dermal fibroblasts at 40 μM, indicating potential applications in skin aging and wound-healing research. It shows strong antioxidant activity by protecting cells from oxidative stress. The compound demonstrates antimicrobial and cytoprotective effects in various cell-based assays. Compared to its aglycone, the 7-O-glucoside moiety modulates potency with a 17-fold difference in xanthine oxidase inhibition assays.
|
| ln Vivo |
In vivo pharmacological data for 6-hydroxyluteolin 7-glucoside remain limited in the published literature. Based on its flavonoid glycoside structure and observed in vitro anti-inflammatory activity through arachidonic acid pathway inhibition, the compound is expected to exhibit systemic anti-inflammatory effects following appropriate administration. The compound's natural abundance in medicinal plants such as Salvia plebeia (up to 2.45% dry weight) suggests potential for oral bioavailability. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic profiles in animal models of inflammation and oxidative stress.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for 6-hydroxyluteolin 7-glucoside typically involves measuring 15-lipoxygenase (15-LOX) activity using spectrophotometric methods. The enzyme is incubated with linoleic acid substrate and varying concentrations of the test compound, and the formation of hydroperoxy fatty acid products is monitored at 234 nm. For xanthine oxidase assays, the compound's inhibitory activity is assessed by measuring uric acid production from xanthine oxidation at 295 nm, with IC50 values calculated from dose-response curves. Arachidonic acid metabolism inhibition is evaluated in leukocyte preparations by quantifying eicosanoid production via HPLC or ELISA.
|
| Cell Assay |
In vitro cellular assays for 6-hydroxyluteolin 7-glucoside typically employ human dermal fibroblasts to assess collagen type I upregulation, with cells treated at 40 μM concentration and collagen expression measured by ELISA or Western blot. For anti-inflammatory activity assessment, leukocyte cultures are treated with the compound and stimulated with relevant agonists, followed by measurement of arachidonic acid metabolites and inflammatory cytokine production. Cytoprotective effects are evaluated using oxidative stress models where cells are exposed to H₂O₂ or other oxidants with and without compound pretreatment, with cell viability assessed by MTT or similar assays.
|
| Animal Protocol |
Published in vivo animal studies for 6-hydroxyluteolin 7-glucoside are not extensively documented. Based on its known anti-inflammatory properties through arachidonic acid metabolism inhibition, potential in vivo models would include rodent models of acute inflammation such as carrageenan-induced paw edema or chronic inflammatory conditions. The compound's natural abundance in Salvia plebeia (up to 2.45% dry weight) enables sufficient material for in vivo studies. Dosing would typically be via oral or intraperitoneal administration, with endpoints including inflammatory cytokine levels, tissue histopathology, and oxidative stress markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6-hydroxyluteolin 7-glucoside are influenced by its flavonoid glycoside structure. The 7-O-glucoside moiety significantly alters pharmacokinetic behavior compared to the aglycone, generally resulting in reduced oral absorption due to the hydrophilic glucose moiety. However, the compound may undergo deglycosylation in the gastrointestinal tract by gut microbiota, releasing the active aglycone for absorption. The molecular weight of 464.38 g/mol and LogP of approximately 0.2 suggest moderate lipophilicity. The compound requires protection from light during storage and is soluble in DMSO at 100 mg/mL.
|
| Toxicity/Toxicokinetics |
Toxicological data for 6-hydroxyluteolin 7-glucoside are limited in the published literature. The compound is reported to have minimal off-target toxicity as a 15-LOX inhibitor. As a naturally occurring flavonoid glycoside found in edible and medicinal plants including tansy and common wheat, it is generally considered to have a favorable safety profile. The compound exhibits low cytotoxicity in cell-based assays. Standard toxicological studies including acute toxicity, sub-chronic toxicity, and genotoxicity assessments would be required for therapeutic development, though such data are not currently published for this specific compound.
|
| References | |
| Additional Infomation |
6-hydroxyluteolin-7-glucoside has been reported to be found in sage, griseorrhiza, and other organisms with available data.
6-Hydroxyluteolin 7-glucoside (CAS# 54300-65-1, molecular formula C₂₁H₂₀O₁₂, molecular weight 464.38) is a flavonoid glycoside derived from plants including tansy and common wheat. The compound inhibits the major pathway of arachidonic acid metabolism in leukocytes and has anti-inflammatory activities. It is a useful tool in natural product research and functional food development. The compound has been reported in sage, griseorrhiza, and other organisms. No clinical trials or regulatory approvals have been identified for this compound. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month. |
| Molecular Formula |
C21H20O12
|
|---|---|
| Molecular Weight |
464.37600
|
| Exact Mass |
464.095
|
| CAS # |
54300-65-1
|
| PubChem CID |
185766
|
| Appearance |
Yellow to orange solid
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
745
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])O[H])O[H])OC1=C(C(=C2C(C([H])=C(C3C([H])=C([H])C(=C(C=3[H])O[H])O[H])OC2=C1[H])=O)O[H])O[H]
|
| InChi Key |
HYPKUHLLPBGDLF-IAAKTDFRSA-N
|
| InChi Code |
InChI=1S/C21H20O12/c22-6-14-17(27)19(29)20(30)21(33-14)32-13-5-12-15(18(28)16(13)26)10(25)4-11(31-12)7-1-2-8(23)9(24)3-7/h1-5,14,17,19-24,26-30H,6H2/t14-,17-,19+,20-,21-/m1/s1
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-5,6-dihydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (215.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1534 mL | 10.7670 mL | 21.5341 mL | |
| 5 mM | 0.4307 mL | 2.1534 mL | 4.3068 mL | |
| 10 mM | 0.2153 mL | 1.0767 mL | 2.1534 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
